Chu Yu-Waye 4

What Happened
Chu Yu‑Waye, Chief Medical Officer of CytomX Therapeutics (CTMX), received equity awards reported on Feb 2, 2026: 75,000 restricted stock units (RSUs) and a 300,000‑share derivative award (reported as a derivative grant, i.e., an option or similar). Both awards were granted at $0.00 purchase price (typical for compensation grants), so no cash was paid by the insider at grant.

Key Details

• Transaction date: February 2, 2026; filing accession: Feb 4, 2026. Reported as grants (code A).
• Awards: 75,000 RSUs (reported at $0.00) and a 300,000 derivative award (reported at $0.00).
• Vesting for the RSUs (F1): 1/3rd vests annually on March 15, with the first vesting March 15, 2027, contingent on continued service.
• Footnote F2: filing notes that 206,000 RSUs are included in the reported amounts.
• Vesting for the derivative award (F3): vests 1/48th each month starting Feb 2, 2026, so fully vested after four years, subject to continued service.
• Shares owned after the transaction: not specified in the provided summary of the filing.
• Timeliness: Filing covers the Feb 2, 2026 grants and was filed Feb 4, 2026; no late‑filing flag indicated in the provided data.

Context

• These are compensation grants, not open‑market purchases or sales. Grants at $0.00 are standard for RSUs/options and represent potential future ownership if vesting conditions are met.
• The 300,000 derivative award is subject to multi‑year vesting and is not immediately exercisable into shares except as it vests; it is not reported as an immediate sale or cashless exercise.
• For retail investors: such awards signal executive compensation alignment with shareholders (vesting over time) but are routine — they do not alone indicate the insider is buying or selling stock on market conviction.